Good MorningThe rebound in equities gained momentum on Thursday after a series of better than expected earnings from some key retailers. The news highlights the differences in company operations more so than a divide in customer habits as those with resonating brands and omnichannel business models have been outperforming the rest of the retail sector. The caveat for investors is that the news from the retail sector highlights a trend within the broader market as well, that of rotation. The FOMC is on track to raise rates to restrictive levels and that is driving rotation from underperforming names into those well-positioned for the new operating environment.
The risk for the market today is the PCE price index. If the market can get past that we may see a test of resistance at the 4,100 level. If the S&P 500 can get above that level a move back up and into the 4,300 to 4,500 should follow. Next week, the market will be on the lookout for another round of key economic data including the Fed's Beige Book, construction spending, and nonfarm payrolls. Featured: The options guide that actually starts at the beginning (Ad) 
|
Finance | |
Buy now and pay later purchase financing provider Affirm (NASDAQ: AFRM) stock is rebounding after bottoming out at $13.64. The buy-now-pay-later (BNPL) platform had a very negative sentiment heading into its fiscal Q3 2022 earnings release on the heels of weak performances from Block (NYSE: SQ) an... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Consumer Discretionary | |
Airbnb, Inc (NASDAQ: ABNB) has been punished for being both a tech stock as well as for being in the tourism industry. Its price was sold off heavily following the announcement of the pandemic and was sold off yet again in December last year when the valuations of many tech stocks cratered. The st... Read the Full Story |
|
Markets | |
RBC Bearings Recovery Gains Momentum
RBC Bearings (NASDAQ: ROLL) is not a large company but its FQ4 results are among the most important at this stage in the earnings cycle. The company makes ball bearings and ball bearing components which isn’t very exciting until you think about all the ... Read the Full Story |
|
|
Consumer Staples | |
Dollar stores are on fire, but does the post-earnings rally have legs?
Shares of Dollar General (NYSE: DG) and Dollar Tree (NASDAQ: DLTR) are rallying the day after both companies reported strong earnings. In late-day trading, DLTR stock was leading the NASDAQ index with a 21% gain. For its own ... Read the Full Story |
|
Markets | |
Are dividend stocks passive income kings? Yes! However, there are a few other types of investments that might fit your needs as well, in addition to dividend investing. Let's take a look at a few different options for passive investment besides dividend stocks.
We'll walk through different types ... Read the Full Story |
|
From Our Partners | | More than 25 candidates were screened for share price between $1 and $5, market cap above $100 million, daily volume over 500,000 shares, and over $10 million in trailing revenue.
Only five stocks cleared every filter, spanning five different sectors. Two are profitable today, and one pays a substantial dividend.
The report also flags what could go wrong with each pick, including dilution and convertible debt. | | See the five stocks that survived this strict revenue screen |
|
Consumer Discretionary | |
Genesco Guides Higher But Fails To Impress
Genesco, Inc (NYSE: GCO), owner of brands like Journeys and Schuh, has proven its place in post-pandemic retail. The company’s brand position and omnichannel offering have it set up to outperform many of its mall-based competitors but there is a p... Read the Full Story |
|
Consumer Discretionary | |
Institutions Like The Look Of Movado Group
The insiders have been selling shares of Movado Group (NYSE: MOV) but so what? The selling has been very light and they still own more than 28% of the company so there is no red flag to worry about. Instead, focus on the institutions and their activity ... Read the Full Story |
|
Markets | | Retail Sector Bottoms On Mixed Results
The Retail Sector (NYSEARCA: XRT) is rebounding but we don’t think investors should cheer too loudly. The move is driven by the combination of oversold markets and mixed results and we don’t see it going very high. While the XRT Retail Sector ETF ... Read the Full Story |
|
Consumer Discretionary | | After sliding close to 40% in value since February, shares of fashion kingpin Ralph Lauren (NYSE: RL) were in need of some good news, and this week they got it. The company reported its fiscal Q4 numbers at the start of Tuesday’s session, and right off the bat, they looked good. EPS for the qu... Read the Full Story |
|
Finance | |
Block, Inc. (SQ), is perhaps one of the most well-known companies in the fintech and blockchain space. Its presence was popularized by its owner and former Twitter CEO Jack Dorsey, but it is at present failing to live up to some investors’ expectations. Block’s share price has been sev... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. | | View Today's Stock Pick |
|
